华蟾素联合顺铂腔内注射治疗恶性胸腹水  

Intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites

作　　者：冉之蓉 

机构地区：[1]重庆钢铁集团总医院肿瘤科,重庆400081

出　　处：《肿瘤》2007年第8期663-665,共3页Tumor

摘　　要：目的：探讨华蟾素联合顺铂腔内注射治疗恶性胸腹水的疗效。方法：将66例恶性胸腹水患者随机分为2组，试验组33例抽取胸腹水后腔内灌注华蟾素20mL和顺铂60mg，每周1次，连续2—4周。对照组33例采用单药顺铂60mg腔内灌注。结果：试验组22例恶性胸水患者治疗有效率86．4％；11例恶性腹水患者治疗有效率72．7％；试验组治疗恶性胸腹水总有效率81．8％，KPS评分提高21例，稳定10例，降低2例。对照组21例恶性胸水患者的有效率为52．4％；12例恶性腹水患者的有效率为41．7％；对照组治疗恶性胸腹水总有效率为48．5％，KPS评分提高9例，稳定12例，降低12例。2组疗效比较，试验组优于对照组（P〈0．05），毒性反应更小（P〈0．05）。结论：华蟾素联合顺铂腔内注射治疗恶性胸腹水疗效满意，副作用小，值得临床推广应用。Objective ：To observe the effect of intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites. Methods ：The sixty six patients were randomly divided into two groups. Patients in the treatment group （ n = 33 ） were infused with 20 mL of Huachansu injection and 60 mg of cisplatin intrapericardially once a week and the treatment lasted for 2-4 weeks. Patients in the control group （ n = 33 ） were infused with 60 mg of cisplatin intrapericardially. Results： For the treatment group, the response rate （complete response ＋ partial respons.e） was 86.4% in 22 cases with malignant pleural effusion and 72.7% （8/11） in 11 cases with malignant ascites. The total response rate was 81.8% （27/33）. The living qualities were improved in 21 cases, stable in 10 cases, and decreased in 2 cases. For the control group, the response rate （complete response ＋ partial response） was 52.4% in 21 cases with malignant pleural effusion and 41.7% in 12 cases with malignant ascites. The total response rate was 48.5%. The living qualities were improved in 9 cases, stable in 12 cases, and decreased in 12 cases. The response rate was gignificantly higher and the toxic reaction was significantly lower in the treatment group than that in the control group （ P 〈 0.05 ）. Conclusion. Intrapercardial infusion of Huachansu injection plus cisplatin achieves satisfactory effects in the treatment of malignant pleural effusion and ascites and has less side effects. It is worthy of clinical application.

关 键 词：肿瘤 胸水 腹水 药物疗法 联合 华蟾素 

分 类 号：R730.59[医药卫生—肿瘤]